Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Prospective memory, emotional valence, and multiple sclerosis.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Company restores access to multiple sclerosis drug after pressure from neurologists.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Pediatric multiple sclerosis.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Predictive value of early brain atrophy on response in patients treated with interferon β.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Epigenetic changes in patients with multiple sclerosis.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.

Pages